deltatrials
Completed PHASE1 INTERVENTIONAL 6-arm NCT03718130

Combination HTNV and PUUV DNA Vaccine

A Phase 1, Randomized Trial to Assess the Safety, Reactogenicity, and Immunogenicity of a Combination HTNV and PUUV DNA Vaccine Candidate Administered by Electroporation

Sponsor: Ichor Medical Systems Incorporated

Conditions Hantaan Virus Disease, Puumala Virus
Interventions Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID) Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM) Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM) Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID) Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID) Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)
Updated 13 times since 2018 Last updated: Jun 9, 2025 Started: Jul 10, 2019 Primary completion: Oct 7, 2022 Completion: Oct 7, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03718130, this PHASE1 trial focuses on Hantaan Virus Disease, Puumala Virus and remains completed. Sponsored by Ichor Medical Systems Incorporated, it has been updated 13 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Aug 2019 · 8 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Dec 2020 · 9 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jun 2022 · 9 months · monthly snapshot~Jun 2022 – ~Jun 2024 · 24 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshot~Jul 2025 – present · 12 months · monthly snapshot

Change History

13 versions recorded

  1. Jul 2025 — Present [monthly]

    Completed PHASE1

    Status: Unknown → Completed

  2. Sep 2024 — Jul 2025 [monthly]

    Unknown PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1

    Status: Unknown Status → Unknown

  4. Jun 2024 — Jul 2024 [monthly]

    Unknown Status PHASE1

    Status: Active Not Recruiting → Unknown Status

  5. Jun 2022 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

▶ Show 8 earlier versions

  1. Sep 2021 — Jun 2022 [monthly]

    Recruiting PHASE1

    Status: Enrolling By Invitation → Recruiting

  2. Jan 2021 — Sep 2021 [monthly]

    Enrolling By Invitation PHASE1

  3. Dec 2020 — Jan 2021 [monthly]

    Enrolling By Invitation PHASE1

  4. Mar 2020 — Dec 2020 [monthly]

    Enrolling By Invitation PHASE1

    Status: Not Yet Recruiting → Enrolling By Invitation

  5. Oct 2019 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE1

  6. Aug 2019 — Oct 2019 [monthly]

    Not Yet Recruiting PHASE1

  7. Dec 2018 — Aug 2019 [monthly]

    Not Yet Recruiting PHASE1

  8. Nov 2018 — Dec 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ichor Medical Systems Incorporated
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • The Geneva Foundation
  • U.S. Army Medical Research and Development Command
  • US Army Medical Research Institute of Infectious Diseases
Data source: U.S. Army Medical Research and Development Command

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations